Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials
Source: SeekingAlpha
2026-01-20 13:00:23 ET
More on Legend Biotech, Arcellx
- Legend Biotech Corporation (LEGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Arcellx: Funded Into 2028 With Strong Clinical Data
- Arcellx, Inc. (ACLX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow
- Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset
- Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma
Read the full article on Seeking Alpha
For further details see:
Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials
Legend Biotech Corporation
NASDAQ: LEGN
LEGN Trading
-0.35% G/L:
$34.50 Last:
1,582,669 Volume:
$34.975 Open:
LEGN Latest News
June 02, 2026 09:30:00 am
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
LEGN Stock Data
$3,309,357,827
166,569,786
N/A
63
N/A
Biotechnology & Life Sciences
Healthcare
US
Somerset
